A Phase I Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Eribulin (Primary) ; Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 30 Oct 2017 Last checked against ClinicalTrials.gov record.
- 26 Oct 2017 Planned End Date changed from 1 Jun 2020 to 30 Jun 2020.
- 26 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Jun 2019.